Showing items 226-235 of 1190 (119 Page(s) Totally)
<< < 18 19 20 21 22 23 24 25 26 27 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-09-04T05:16:30Z |
Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients
|
Yeo Y.H.; Tseng T.-C.; Hosaka T.; Cunningham C.; Fung J.Y.Y.; Ho H.J.; Kwak M.-S.; Trinh H.N.; Ungtrakul T.; Yu M.-L.; Kobayashi M.; Le A.K.; Henry L.; Li J.; Zhang J.; Sriprayoon T.; Jeong D.; Tanwandee T.; Gane E.; Cheung R.C.; Wu C.-Y.; Lok A.S.; Lee H.-S.; Suzuki F.; Yuen M.-F.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2021-09-02T00:04:05Z |
Improved design and in vivo animal tests of bone-guided cochlear implant microsystem with monopolar biphasic multiple stimulation and neural action potential acquisition
|
Wang S.-H;Huang Y.-K;Chen C.-Y;Lee C.-F;Yang C.-H;Hung C.-C;Liu C.-H;Ker M.-D;Wu C.-Y.; Wang S.-H; Huang Y.-K; Chen C.-Y; Lee C.-F; Yang C.-H; Hung C.-C; Liu C.-H; Ker M.-D; Wu C.-Y.; CHIA-HSIANG YANG |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Hsu C.-H.; Chen J.; Wu C.-Y.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:22Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; Lee P.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Shen Y.-C.; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:21Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:18Z |
Effect of thalidomide in hepatocellular carcinoma: Assessment with power Doppler US and analysis of circulating angiogenic factors
|
Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Hsieh F.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-30T06:17:04Z |
Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors
|
Shen H.; Hsu H.-C.; Tai Y.-J.; Kuo K.-T.; Wu C.-Y.; YEN-LING LAI; Chiang Y.-C.; Chen Y.-L.; Cheng W.-F. |
Showing items 226-235 of 1190 (119 Page(s) Totally)
<< < 18 19 20 21 22 23 24 25 26 27 > >>
View [10|25|50] records per page
